Preview Mode Links will not work in preview mode

Medscape InDiscussion: Schizophrenia

Aug 2, 2022

Drs John Kane and Christoph U. Correll discuss the major metabolic and neurologic risks associated with antipsychotic medications for patients diagnosed with schizophrenia.

Relevant disclosures can be found with the episode show notes on Medscape ( The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.



Understanding the Effects of Antipsychotics on Appetite Control

Food and Drug Administration's Obesity Drug Guidance Document

Risk of Weight Gain for Specific Antipsychotic Drugs: A Meta-analysis

Diabetes and Schizophrenia

Brain Insulin Action: Implications for the Treatment of Schizophrenia

Obesity as a Risk Factor for Accelerated Brain Ageing in First-Episode Psychosis -- A Longitudinal Study

Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission,be%20explored%20in%20prospective%20studies

Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort

Incidence and Severity of Tardive Dyskinesia Increase With Age

Extrapyramidal Symptoms With Atypical Antipsychotics: Incidence, Prevention and Management